Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Status
Conditions
Details and patient eligibility
About
The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.
Full description
The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria for Pancreatic Cancer Patients:
- Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis.
- Patients will have had no prior treatment or surgery
Inclusion Criteria for Healthy Subjects:
- Subjects will have no prior history of any cancer
Exclusion criteria
Exclusion Criteria for Pancreatic Cancer Patients
- Any prior treatment for pancreatic cancer
- Poorly controlled diabetes
Exclusion Criteria for Healthy Subjects
- Poorly controlled diabetes
Trial design
0 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal